Hjem › Ikke-småcellet lungekreft › Illinois › Bloomington
Kliniske studier for Ikke-småcellet lungekreft i Bloomington, IL
11 studier for Ikke-småcellet lungekreft søker deltakere på steder i og rundt Bloomington (innen ca. 30 miles). Åpne et studie for å se hvem som kan delta og hvordan du kontakter studieteamet.
Offisiell studietekst (engelsk)
Rekrutterer til et studie her? Få det fremtredende øverst på siden – $99 i 30 dager →
Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial
RekruttererFase 3
- Illinois CancerCare-Bloomington, Bloomington
- Carle BroMenn Medical Center, Normal · 2 mi unna
- Carle Cancer Institute Normal, Normal · 2 mi unna
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
RekruttererFase 3
- Illinois CancerCare-Bloomington, Bloomington
A Study of Targeted Post-Surgery Radiation Therapy for Non-Small Cell Lung Cancer With Remaining Lymph Node Cancer After Treatment
RekruttererFase 2
- OSF Saint Joseph Medical Center, Bloomington
- Illinois CancerCare-Bloomington, Bloomington
A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
RekruttererFase 3
- Illinois CancerCare- Bloomington, Bloomington
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
RekruttererFase 3
- Illinois CancerCare - Bloomington, Bloomington
Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
RekruttererFase 2
- Illinois CancerCare-Bloomington, Bloomington
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
RekruttererFase 2
- Illinois CancerCare-Bloomington, Bloomington
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)
RekruttererFase 2
- Illinois CancerCare-Bloomington, Bloomington
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
RekruttererFase 2/3
- Illinois CancerCare-Bloomington, Bloomington
- Carle BroMenn Medical Center, Normal · 2 mi unna
- Carle Cancer Institute Normal, Normal · 2 mi unna
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
RekruttererFase 2
- Illinois CancerCare-Bloomington, Bloomington
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
RekruttererObservasjonsstudie
- Illinois CancerCare-Bloomington, Bloomington
- Carle Cancer Institute Normal, Normal · 2 mi unna
Ikke-småcellet lungekreft-studier i andre byer
- Houston, TX145 studier
- New York City, NY121 studier
- Arlington, VA104 studier
- Nashville, TN97 studier
- Boston, MA90 studier
- Los Angeles, CA87 studier
- St. Louis, MO73 studier
- Chicago, IL61 studier
- Baltimore, MD60 studier
- San Antonio, TX59 studier
- Columbus, OH57 studier
- Washington, DC55 studier
Andre studier i Bloomington
- Lungekreft9 studier
- Prostatakreft7 studier
- Kolorektal kreft7 studier
- Plateepitelcancer i hode og hals6 studier
- Brystkreft5 studier
- Pankreaskreft5 studier
- Melanom5 studier
- Hypofarynxcancer5 studier
- Larynxcancer5 studier
- Munnhulekreft5 studier
- Blærekreft4 studier
- Akut myelogen leukemi4 studier
Fra ClinicalTrials.gov, data hentet 6. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.